Antimicrobials in urogenital infections

International Journal of Antimicrobial Agents

Volumn 38, Issue SUPPL., 2011, Pages 3-10

  Wagenlehner, Florian M E ^a   Wullt, Björn ^b   Perletti, Gianpaolo ^c  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Antibiotic treatment; Antimicrobial substances; Male genital infection; Urinary tract infection

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOPENICILLIN; AMOXICILLIN; AMPICILLIN; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFALEXIN; CEFOTIAM; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; ENOXACIN; ERTAPENEM; FOSFOMYCIN; FOSFOMYCIN TROMETAMOL; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; NITROFURANTOIN; NORFLOXACIN; PENICILLIN DERIVATIVE; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; PIVMECILLINAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPECTINOMYCIN; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERICIDAL ACTIVITY; CHLAMYDIA; CYSTITIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG INDICATION; DRUG METABOLISM; ESCHERICHIA COLI; GENITAL TRACT INFECTION; GONORRHEA; HUMAN; LACTIC ACIDOSIS; LIVER TOXICITY; LUNG TOXICITY; MYCOPLASMA; NEPHROTOXICITY; NONHUMAN; OPTIC NERVE DISEASE; OTOTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSTATITIS; PYELONEPHRITIS; SINGLE DRUG DOSE; UREAPLASMA INFECTION; URINARY TRACT INFECTION; UROGENITAL TRACT INFECTION;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; FEMALE; FEMALE UROGENITAL DISEASES; HUMANS; MALE; MALE UROGENITAL DISEASES; URINARY TRACT INFECTIONS;

EID: 82655187428     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2011.09.004     Document Type: Article

References (95)

1. J. Li, R.L. Nation, J.D. Turnidge, R.W. Milne, K. Coulthard, and C.R. Rayner Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections Lancet Infect Dis 6 2006 589 601
2. K. Gupta, T.M. Hooton, and W.E. Stamm Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections Ann Intern Med 135 2001 41 50 (Pubitemid 32619282)
3. T.M. Hooton The current management strategies for community-acquired urinary tract infection Infect Dis Clin North Am 17 2003 303 332 (Pubitemid 36760185)
4. G. Kahlmeter An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project J Antimicrob Chemother 51 2003 69 76 (Pubitemid 36163829)
5. J.W. Warren, E. Abrutyn, J.R. Hebel, J.R. Johnson, A.J. Schaeffer, and W.E. Stamm Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women, Infectious Diseases Society of America (IDSA) Clin Infect Dis 29 1999 745 758 (Pubitemid 30256361)
6. D.A. Talan, W.E. Stamm, T.M. Hooton, G.J. Moran, T. Burke, and A. Iravani Comparison of ciprofloxacin (7 days) and trimethoprimsulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial JAMA 283 2000 1583 1590 (Pubitemid 30161514)
7. K.G. Naber, G. Schito, H. Botto, J. Palou, and T. Mazzei Surveillance study in Europe and Brazil on clinical aspects and antimicrobial resistance epidemiology in females with cystitis (ARESC): implications for empiric therapy Eur Urol 54 2008 1164 1175
8. K. McLuskey, S. Cameron, F. Hammerschmidt, and W.N. Hunter Structure and reactivity of hydroxypropylphosphonic acid epoxidase in fosfomycin biosynthesis by a cation- and flavin-dependent mechanism Proc Natl Acad Sci USA 102 2005 14221 14226 (Pubitemid 41429679)
9. S.S. Patel, J.A. Balfour, and H.M. Bryson Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections Drugs 53 1997 637 656 (Pubitemid 27145957)
10. G.C. Schito Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int J Antimicrob Agents 22 Suppl. 2 2003 79 83
11. D. Ungheri, E. Albini, and G. Belluco In-vitro susceptibility of quinolone-resistant clinical isolates of Escherichia coli to fosfomycin trometamol J Chemother 14 2002 237 240 (Pubitemid 34734565)
12. K.G. Naber, G. Schito, H. Botto, J. Palou, and T. Mazzei Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy Eur Urol 54 2008 1164 1175
13. H. Knothe, V. Schafer, A. Sammann, and P.M. Shah Influence of fosfomycin on the intestinal and pharyngeal flora of man Infection 19 1991 18 20
14. H. Hof Antimicrobial therapy with nitroheterocyclic compounds, for example, metronidazole and nitrofurantoin Immun Infekt 16 1988 220 225 (Pubitemid 19023155)
15. J.D. Conklin The pharmacokinetics of nitrofurantoin and its related bioavailability Antibiot Chemother 25 1978 233 252
16. J. Kashanian, P. Hakimian, M. Blute Jr., J. Wong, H. Khanna, and G. Wise Nitrofurantoin: the return of an old friend in the wake of growing resistance BJU Int 102 2008 1634 1637
17. T. Mazzulli, M. Skulnick, G. Small, W. Marshall, D.J. Hoban, and G.G. Zhanel Susceptibility of community Gram-negative urinary tract isolates to mecillinam and other oral agents Can J Infect Dis 12 2001 289 292 (Pubitemid 33111427)
18. G.J. Williams, L. Wei, A. Lee, and J.C. Craig Long-term antibiotics for preventing recurrent urinary tract infection in children Cochrane Database Syst Rev 3 2006 CD001534
19. A. Koulaouzidis, S. Bhat, J. Moschos, C. Tan, and A. De Ramon Nitrofurantoininduced lung- and hepatotoxicity Ann Hepatol 6 2007 119 121
20. E. Mavromanolakis, S. Maraki, G. Samonis, Y. Tselentis, and A. Cranidis Effect of norfloxacin, trimethoprimsulfamethoxazole and nitrofurantoin on fecal flora of women with recurrent urinary tract infections J Chemother 9 1997 203 207 (Pubitemid 27288410)
21. J. Sjovall, B. Huitfeldt, L. Magni, and C.E. Nord Effect of beta-lactam prodrugs on human intestinal microflora Scand J Infect Dis Suppl 49 1986 73 84 (Pubitemid 17224652)
22. B.G. Spratt The mechanism of action of mecillinam J Antimicrob Chemother 3 Suppl. B 1977 13 19 (Pubitemid 8145185)
23. W. Graninger Pivmecillinam - therapy of choice for lower urinary tract infection Int J Antimicrob Agents 22 Suppl. 2 2003 73 78
24. A. Sullivan, C. Edlund, B. Svenungsson, L. Emtestam, and C.E. Nord Effect of perorally administered pivmecillinam on the normal oropharyngeal, intestinal and skin microflora J Chemother 13 2001 299 308 (Pubitemid 32577096)
25. R.N. Jones, K.C. Kugler, M.A. Pfaller, and P.L. Winokur Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY Antimicrobial Surveillance Program, 1997 Diagn Microbiol Infect Dis 35 1999 55 63 (Pubitemid 29435942)
26. K.A. Gordon, and R.N. Jones Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America, Results from the SENTRY Antimicrobial Surveillance Program (2000) Diagn Microbiol Infect Dis 45 2003 295 301 (Pubitemid 36555682)
27. D. Mathai, R.N. Jones, and M.A. Pfaller Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America) Diagn Microbiol Infect Dis 40 2001 129 136 (Pubitemid 32735552)
28. E. Bouza, R. San Juan, P. Munoz, A. Voss, and J. Kluytmans A European perspective on nosocomial urinary tract infections I. Report on the microbiology workload, etiology and antimicrobial susceptibility (ESGNI-003 study). European Study Group on Nosocomial Infections Clin Microbiol Infect 7 2001 523 531 (Pubitemid 34960342)
29. F.M. Wagenlehner, A. Niemetz, A. Dalhoff, and K.G. Naber Spectrum and antibiotic resistance of uropathogens from hospitalized patients with urinary tract infections: 1994-2000 Int J Antimicrob Agents 19 2002 557 564 (Pubitemid 34831661)
30. T.E. Bjerklund Johansen, M. Cek, K. Naber, L. Stratchounski, M.V. Svendsen, and P. Tenke Prevalence of hospital-acquired urinary tract infections in urology departments Eur Urol 51 2007 1100 1111 [discussion 1112]
31. G.R. Donowitz, and G.L. Mandell Beta-lactam antibiotics (1) N Engl J Med 318 1988 419 426
32. D. Nathwani, and M.J. Wood Penicillins. A current review of their clinical pharmacology and therapeutic use Drugs 45 1993 866 894 (Pubitemid 23219070)
33. J.W. Tapsall, E.A. Limnios, M.M. Lahra, D. Dorji, H.M. Abu Bakar, and B. Guillard Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific and South East Asian Regions, 2009 Commun Dis Intell 35 2011 2 7
34. A. Sullivan, C. Edlund, and C.E. Nord Effect of antimicrobial agents on the ecological balance of human microflora Lancet Infect Dis 1 2001 101 114 (Pubitemid 33586045)
35. A. Louie, P. Kaw, W. Liu, N. Jumbe, M.H. Miller, and G.L. Drusano Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection Antimicrob Agents Chemother 45 2001 845 851 (Pubitemid 32182035)
36. W.F. Marshall, and J.E. Blair The cephalosporins Mayo Clin Proc 74 1999 187 195 (Pubitemid 29085217)
37. R.N. Jones, and D.A. Preston The antimicrobial activity of cephalexin against old and new pathogens Postgrad Med J 59 Suppl. 5 1983 9 15 (Pubitemid 14207317)
38. W. Brumfitt, J.M. Hamilton-Miller, R.A. Gargan, J. Cooper, and G.W. Smith Longterm prophylaxis of urinary infections in women: comparative trial of trimethoprim, methenamine hippurate and topical povidone-iodine J Urol 130 1983 1110 1114 (Pubitemid 14207235)
39. J.M. Brogard, F. Jehl, B. Willemin, A.M. Lamalle, J.F. Blickle, and H. Monteil Clinical pharmacokinetics of cefotiam Clin Pharmacokinet 17 1989 163 174 (Pubitemid 19248017)
40. C.M. Perry, and R.N. Brogden Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy Drugs 52 1996 125 158
41. A. Molavi Cephalosporins: rationale for clinical use Am Fam Physician 43 1991 937 948
42. M.N. Dudley, and S.L. Barriere Cefotaxime: microbiology, pharmacology, and clinical use Clin Pharm 1 1982 114 124 (Pubitemid 12025126)
43. R.N. Brogden, and A. Ward Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration Drugs 35 1988 604 645
44. E.C. Chocas, C.M. Paap, and P.J. Godley Cefpodoxime proxetil: a new, broadspectrum, oral cephalosporin Ann Pharmacother 27 1993 1369 1377 (Pubitemid 23336350)
45. R.C. Owens Jr., C.H. Nightingale, and D.P. Nicolau Ceftibuten: an overview Pharmacotherapy 17 1997 707 720 (Pubitemid 27318964)
46. E. Radwanski, M. Teal, M. Affrime, M. Cayen, and C.C. Lin Multiple-dose pharmacokinetics of ceftibuten in healthy adults and geriatric volunteers Am J Ther 1 1994 42 48
47. K. Chugh, and S. Agrawal Cefpodoxime: pharmacokinetics and therapeutic uses Indian J Pediatr 70 2003 227 231 (Pubitemid 36560150)
48. E. Bergogne-Berezin Structure-activity relationship of ceftazidime. Consequences on the bacterial spectrum Presse Med 17 1988 1878 1882 (Pubitemid 18267121)
49. M.A. Wynd, and J.A. Paladino Cefepime: a fourth-generation parenteral cephalosporin Ann Pharmacother 30 1996 1414 1424 (Pubitemid 27020007)
50. B. Murthy, and A. Schmitt-Hoffmann Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity Clin Pharmacokinet 47 2008 21 33 (Pubitemid 350260886)
51. J.D. Pitout, and K.B. Laupland Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public health concern Lancet Infect Dis 8 2008 159 166 (Pubitemid 351249250)
52. T. Kumagai, S. Tamai, T. Abe, and M. Hikida Current status of oral carbapenem development Curr Med Chem Anti-Infect Agents 1 2002 1 14
53. M.L. Hammond Ertapenem: a group 1 carbapenem with distinct antibacterial and pharmacological properties J Antimicrob Chemother 53 Suppl. 2 2004 ii7 ii9
54. P.M. Shah, and R.D. Isaacs Ertapenem, the first of a new group of carbapenems J Antimicrob Chemother 52 2003 538 542 (Pubitemid 37258409)
55. W.C. Hellinger, and N.S. Brewer Carbapenems and monobactams: imipenem, meropenem, and aztreonam Mayo Clin Proc 74 1999 420 434 (Pubitemid 29162543)
56. R.N. Jones, H.S. Sader, and T.R. Fritsche Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various betalactamase resistance mechanisms Diagn Microbiol Infect Dis 52 2005 71 74 (Pubitemid 40692744)
57. M.P. Mingeot-Leclercq, Y. Glupczynski, and P.M. Tulkens Aminoglycosides: activity and resistance Antimicrob Agents Chemother 43 1999 727 737 (Pubitemid 29165732)
58. R. Benveniste, and J. Davies Structure-activity relationships among the aminoglycoside antibiotics: role of hydroxyl and amino groups Antimicrob Agents Chemother 4 1973 402 409
59. M.P. Mingeot-Leclercq, and P.M. Tulkens Aminoglycosides: nephrotoxicity Antimicrob Agents Chemother 43 1999 1003 1012 (Pubitemid 29214718)
60. G.A. Verpooten, R.A. Giuliano, L. Verbist, G. Eestermans, and M.E. De Broe Once-daily dosing decreases renal accumulation of gentamicin and netilmicin Clin Pharmacol Ther 45 1989 22 27 (Pubitemid 19047142)
61. S.H. Sha, and J. Schacht Stimulation of free radical formation by aminoglycoside antibiotics Hear Res 128 1999 112 118 (Pubitemid 29083253)
62. G. Perletti, A. Vral, M.C. Patrosso, E. Marras, I. Ceriani, and P. Willems Prevention and modulation of aminoglycoside ototoxicity Mol Med Rep 1 2008 3 13
63. K.G. Naber, and D. Adam Classification of fluoroquinolones Int J Antimicrob Agents 10 1998 255 257 (Pubitemid 29048266)
64. L.Y. Park-Wyllie, D.N. Juurlink, A. Kopp, B.R. Shah, T.A. Stukel, and C. Stumpo Outpatient gatifloxacin therapy and dysglycemia in older adults N Engl J Med 354 2006 1352 1361
65. F. Van Bambeke, J.M. Michot, J. Van Eldere, and P.M. Tulkens Quinolones in 2005: an update Clin Microbiol Infect 11 2005 256 280 (Pubitemid 40443832)
66. A.O. Okhamafe, J.O. Akerele, and C.S. Chukuka Pharmacokinetic interactions of norfloxacin with some metallic medicinal agents Int J Pharma 68 1991 11 18
67. F. Sorgel, and M. Kinzig Pharmacokinetics of gyrase inhibitors, part 2: renal and hepatic elimination pathways and drug interactions Am J Med 94 1993 56S 69S (Pubitemid 23089430)
68. K.G. Naber Which fluoroquinolones are suitable for the treatment of urinary tract infections? Int J Antimicrob Agents 17 2001 331 341 (Pubitemid 32293535)
69. T.A. Stamey, S.R. Bushby, and J. Bragonje The concentration of trimethoprim in prostatic fluid: nonionic diffusion or active transport? J Infect Dis 128 Suppl. 1973 686 692
70. T.A. Stamey, E.M. Meares Jr., and D.G. Winningham Chronic bacterial prostatitis and the diffusion of drugs into prostatic fluid J Urol 103 1970 187 194
71. F.M. Wagenlehner, F. Kees, W. Weidner, C. Wagenlehner, and K.G. Naber Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers Int J Antimicrob Agents 31 2008 21 26 (Pubitemid 350236732)
72. N.A. Cross, D.J. Kellock, G.R. Kinghorn, M. Taraktchoglou, E. Bataki, and K.M. Oxley Antimicrobial susceptibility testing of Chlamydia trachomatis using a reverse transcriptase PCR-based method Antimicrob Agents Chemother 43 1999 2311 2313 (Pubitemid 29421223)
73. J.D. Smilack Trimethoprimsulfamethoxazole Mayo Clin Proc 74 1999 730 734
74. K.G. Naber, G.C. Schito, L. Gualco on behalf of the ARESC working group An international survey on etiology and susceptibility of uropathogens isolated from women with uncomplicated UTI: the ARESC study Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Chicago, Ilinois, USA 2007
75. G. Kahlmeter Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study Int J Antimicrob Agents 22 Suppl. 2 2003 49 52
76. J.A. Karlowsky, L.J. Kelly, C. Thornsberry, M.E. Jones, and D.F. Sahm Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States Antimicrob Agents Chemother 46 2002 2540 2545 (Pubitemid 34793461)
77. J.A. Karlowsky, L.J. Kelly, C. Thornsberry, M.E. Jones, A.T. Evangelista, and I.A. Critchley Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States, Tracking Resistance in the United States Today. The Surveillance Network Int J Antimicrob Agents 19 2002 21 31 (Pubitemid 34119067)
78. A. Hofstetter, A. Friesen, G.B. Bishop-Freudling, and H. Vergin Co-trimoxazole concentration in the prostatic fluid of patients with subacute and chronic prostatitis Fortschr Med 102 1984 244 246 (Pubitemid 14154447)
79. E.M. Meares Jr. Prostatitis: review of pharmacokinetics and therapy Rev Infect Dis 4 1982 475 483
80. K.G. Naber, A. Bartnicki, W. Bischoff, M. Hanus, S. Milutinovic, and F. van Belle Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections Int J Antimicrob Agents 23 Suppl. 1 2004 S41 S53
81. K.G. Naber, B. Bergman, M.C. Bishop, T.E. Bjerklund-Johansen, H. Botto, and B. Lobel EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU) Eur Urol 40 2001 576 588 (Pubitemid 34289761)
82. P.E. Hermans, and M.P. Wilhelm Vancomycin Mayo Clin Proc 62 1987 901 905 (Pubitemid 18011656)
83. M.J. Wood The comparative efficacy and safety of teicoplanin and vancomycin J Antimicrob Chemother 37 1996 209 222 (Pubitemid 26123160)
84. D. Shinabarger Mechanism of action of the oxazolidinone antibacterial agents Expert Opin Investig Drugs 8 1999 1195 1202 (Pubitemid 29410576)
85. J.E. Conte Jr., J.A. Golden, J. Kipps, and E. Zurlinden Intrapulmonary pharmacokinetics of linezolid Antimicrob Agents Chemother 46 2002 1475 1480 (Pubitemid 34415331)
86. A.P. MacGowan Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections J Antimicrob Chemother 51 Suppl. 2 2003 ii17 ii25
87. S. Tsiodras, H.S. Gold, G. Sakoulas, G.M. Eliopoulos, C. Wennersten, and L. Venkataraman Linezolid resistance in a clinical isolate of Staphylococcus aureus Lancet 358 2001 207 208 (Pubitemid 32718546)
88. J. Carson, J. Cerda, J.H. Chae, M. Hirano, and P. Maggiore Severe lactic acidosis associated with linezolid use in a patient with the mitochondrial DNA A2706G polymorphism Pharmacotherapy 27 2007 771 774 (Pubitemid 46700971)
89. S.E. Beekmann, D.N. Gilbert, and P.M. Polgreen Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey Diagn Microbiol Infect Dis 62 2008 407 410
90. H. Lode, N. Von der Hoh, S. Ziege, K. Borner, and C.E. Nord Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora Scand J Infect Dis 33 2001 899 903 (Pubitemid 34083321)
91. N.E. Allen, J.N. Hobbs, and W.E. Alborn Jr. Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032 Antimicrob Agents Chemother 31 1987 1093 1099 (Pubitemid 17099584)
92. D.R. Snydman, N.V. Jacobus, L.A. McDermott, J.R. Lonks, and J.M. Boyce Comparative In vitro activities of daptomycin and vancomycin against resistant Gram-positive pathogens Antimicrob Agents Chemother 44 2000 3447 3450 (Pubitemid 33009511)
93. K.G. Naber, B.I. Eisenstein, and F.P. Tally Daptomycin versus ciprofloxacin in the treatment of complicated urinary tract infection due to Gram-positive bacteria Infect Dis Clin Pract 12 2004 322 327 (Pubitemid 39507293)
94. J.C. Nickel, M. Patel, and M. Cameron Chronic prostatitis/chronic pelvic pain syndrome: finding a way forward in the United Kingdom: report from the first United Kingdom symposium on chronic prostatitis, January 30, 2008, London, United Kingdom Rev Urol 10 2008 160 163
95. K.N. Agwuh, and A. MacGowan Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines J Antimicrob Chemother 58 2006 256 265 (Pubitemid 44294934)